[14] Ofatumumab (Kesimpta 20 mg solution for injection in pre-filled syringe/pen) is indicated for the treatment of relapsing forms of multiple sclerosis in adults.

[17][18] Treatment with ofatumumab has been shown to rapidly deplete B-cells[17][18] which aids MS pathogenesis by influencing and regulating different autoimmune process such as T-cell production and APC activity.

[16][23] Likewise it is also advised that doctors watch cautiously for small bowel obstruction, neutropenia, thrombocytopenia, infusion reactions or an increased risk for infection.

[28][29] Ofatumumab (Arzerra) was then approved in the European Union in June 2010,[14] in the United Kingdom in April 2010,[6] and in Canada in August 2012.

[35][36] Ofatumumab (Kesimpta) was approved for the treatment of relapsing forms of multiple sclerosis in adults in the United States in August 2020.

[11] Ofatumumab (Arzerra) was transitioned to an oncology access program to make it available at no cost to chronic lymphocytic leukemia patients in the U.S.[39]